You're here because you want the facts.

SURGENEX® created SurForce®, an amniotic membrane injectable allograft, using our patent-pending Excellion® Process. SurForce® is a minimally manipulated product regulated under the FDA, which allows Surgenex® to sell approved allograft products with confidence to Healthcare Providers. If you are a Healthcare Provider, please visit for a detailed overview.

Surgenex Products helps women
SurForce® is an injectable flowable Amniotic Membrane Allograft that is derived from a donated placenta obtained via C-section delivery. more…
SurForce® is an amniotic membrane allograft that can help protect, cushion, or supplement damaged tissues more…
If you have experienced previous treatments for your condition such as steroidal injections or PRP injections, a procedure with SurForce® will be quite similar. more…
Surgenex Products helps men

As with any condition or injury, a patient must consult their Primary Care Physician or qualified Healthcare Provider for medical advice. If you feel you are a candidate for SurForce® injections, schedule a visit with your Provider to talk about the potential benefits and outcomes of Amniotic Membrane Allografts.

On your initial visit, you and your Provider may discuss your medical history, chief complaints, and any alternative treatments you have used previously to treat your current conditions. Initial or subsequent visits may also include a review of findings to discuss diagnostic imaging reports, treatment options, and a treatment plan. more…
If you feel Amniotic Membrane Allograft will benefit you, ask your Provider today if they are using SurForce®. If not, we will be happy to refer you to the nearest SurForce® Provider.
Surgenex Products helps women
SurForce® is injected into the affected area using a thin-gauge needle. Providers may also use diagnostic imaging to assist the procedure.
SurForce® may be useful for patients who need to see a specialist in Podiatric, Sports medicine, or Orthopaedic medicine.
All SurForce® patients should comply with their customized treatment plan to ensure the best possible outcome. more…
Surgenex can help you find a Doctor
Click here to view the most frequently asked questions concerning SurForce®. As always, talk to your Physician to ask any questions about your health.
To find a Health Care Provider near you that specializes in Amniotic Allograft treatments, call (877) 880-1862 to speak with one of our representatives.
If you are undecided, always consult your Physician with specific questions concerning your health.

frequently asked questions


SurForce® is a cryopreserved injectable derived from Amniotic Membrane Tissue.


For patient outcomes and success stories, please contact the SurForce® Healthcare Provider nearest you. You can also peruse through our patient testimonial section here.


The easiest way to get started is by filling out the contact questionnaire found here. We can identify the nearest SurForce® Providers in your area. A Provider will contact you shortly to address any of your questions or concerns. Surgenex distributes its products exclusively to verified medical facilities.


Our bodies naturally degenerate over time. The regenerative processes that were once vibrant and energetic in our youth become slower and impeded as we age.


Your Provider may or may not recommend post-treatment rehabilitation. This decision will depend heavily upon the injured area and its pathology/etiology, as well as your current physical health status. Patients should work with their Healthcare Provider to determine if rehab will be necessary and/or beneficial.


Depending on the etiology, pathology, and severity of the chief complaint, each patient will be unique. Healthcare Providers can gather subjective and objective information such as patient history, orthopaedic examinations, diagnostic imaging, and lab results to assess and determine the patient’s needs. Based on these findings, Healthcare Providers can specify an appropriate treatment plan. Costs associated with specific procedures may depend on these variables. For specifics, contacting the nearest Provider of SurForce® for a consultation is recommended.


Depending on the affected region, or if there are multiple locations needing an injection, the treatment procedure can be administered during a standard office visit. Specific times may vary depending on factors inherent to the complications of the patient’s needs. The application of the treatment is non-surgical, and requires no pre-treatment preparation time.


There are several advantages to using Amniotic Membrane tissues rather than invasive medical procedures. Unlike pharmaceuticals and lengthy surgical procedures, to date no negative side effects have been reported with amniotic membrane allografts.


As with any treatment modality in Healthcare, there is always an inherent risk. It is understood from research, amniotic membrane is considered immune-evasive, and that no adverse side effects are evident. Furthermore, SurForce® maintains the highest standards of safety in our industry, exceeding the FDA’s minimum safety requirements.


Surgenex uses the Excellion® Process to produce SurForce®. This patent-pending process is a highly manual and surgical process that isolates the amniotic membrane layer of the placenta. No other portion of the placenta is utilized.


Research shows that amniotic membrane tissue allografts contain extracellular matrices including growth factors, anti-fibrotics , anti-microbials, are immune-evasive, and have anti-inflammatory properties.

Research also shows it has the potential to repair articular cartilage. Please peruse our Research section here for research articles related to the incredible benefits of amniotic membrane tissue allografts.


Surgenex Product SurForce Amniotic Membrane Injections

Top Scientists & Research Universities
Continue to study & support Amniotic Membrane Products

Common Clinical Applications for Treatment

*The use of amniotic tissue in orthopaedic surgery has increased in recent years. source..
Orthopaedics Surgery Increased
*The use of amniotic tissue products in sports medicine has increased in recent years source..
Sports Medicine Treatment Increased
Podiatry Treatment Increased
*The use of amniotic tissue products in podiatry has increased in recent years source..

Amniotic Membrane Tissue Allografts Features

Features SurForce PRP BMA
Help Support YES Yes X
Help Protect YES X X
Help Cushion YES X X
15 min 1-2 hrs 2-4 hrs

Surgenex® Research

Amniotic membrane allografts
is shaping the future of healthcare!

Surgenex® Amniotic Membrane Research

Amniotic membrane allograft tissue has been an accepted method of treatment since the early 1900s. The healthcare community has benefited from the tissue regeneration outcomes in specialties such as surgery, orthopedics, pain management, burn care, eye, as well as dental. More recently, Podiatric Physicians have been effectively applying these allografts to patients with diabetic foot ulcers. These treatments are yielding paradigm-shifting outcomes for their patients.

Amniotic membrane tissue injections have been growing in popularity over the past few decades Research and development have increased opportunities and discovered a variety of ground-breaking applications.

Utilizing the latest research and implementing efficient operations, SURGENEX® will focus on innovative research-proven products.

Explore the research and articles below involving the use of amniotic allograft tissue and how it plays an impactful role in the future of regenerative medicine.

National Center for Biotechnology Information

Research - Data - Clinical Studies

Discover What Top Scientist are Saying

Discover what the top scientist, researchers and research universities are saying about the future of amniotic membrane products. SurForce® is an injectable flowable Amniotic Membrane Allograft which is used for a wide variety of clinical applications including:

  • Orthopedics
  • Sports Medicine
  • Podiatry
  • Pain Management

Format: Abstract
Publish: January 2015 10.1016/j.cpm.2014.09.002.
Source: Research Article

Unsuccessful healing represents a significant medical dilemma for both patients and clinicians and create a financial burden on the health care system. Despite the efforts of physicians, many injuries fail to heal with standard care alone. For decades human amniotic membrane composed of both amnion and chorion has shown remarkable therapeutic potential, but only recent preservation methods have allowed its widespread use. Variations in configurations and the ability to micronize the material allow clinical uses that were previously not possible. Although there are limited data available regarding most amniotic membrane-based products, there is substantial preclinical and clinical evidence supporting the rationale and effectiveness of dHACM allograft as a treatment modality. The rapidly growing body of evidence suggests that the properties inherent in dHACM promote tissue regeneration and healing, recruiting patients' own stem cells into the wounded area. Randomized controlled trials evaluating dHACM now include more than 200 patients collectively and the results consistently show improved healing. Use of dHACM has been shown to be more clinically effective and cost-effective than other frequently used advanced wound care products. This cost-effectiveness results from dHACM showing higher healing rates and more rapid healing than other advanced wound care products. Cost-effectiveness is also enhanced through the availability of grafts of multiple sizes, which reduces wastage, and through ease of handling and storage for clinical use. Ongoing and future studies will further define and establish the value of amniotic membrane for chronic tissue repair and regeneration.

Format: Abstract
Publish: April 2017 10.1177/0363546517697682.
Author information
  1. School of Medicine & Health Sciences, George Washington University, Washington, District of Columbia, USA.
  2. Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  3. Osiris Therapeutics Inc, Columbia, Maryland, USA.
Source: Research Article


Placenta has a long history of use for treating burns and wounds. It is a rich source of collagen and other extracellular matrix proteins, tissue reparative growth factors, and stem cells, including mesenchymal stem cells (MSCs). Recent data show its therapeutic potential for orthopaedic sports medicine indications.


To provide orthopaedic surgeons with an anatomic description of the placenta, to characterize its cellular composition, and to review the literature reporting the use of placenta-derived cells and placental tissue allografts for orthopaedic sports medicine indications in animal models and in humans.

STUDY DESIGN: Systematic review.


Using a total of 63 keyword combinations, the PubMed and MEDLINE databases were searched for published articles describing the use of placental cells and/or tissue for orthopaedic sports medicine indications. Information was collected on placental tissue type, indications, animal model, study design, treatment regimen, safety, and efficacy outcomes. Results were categorized by indication and subcategorized by animal model.


Outcomes for 29 animal studies and 6 human studies reporting the use of placenta-derived therapeutics were generally positive; however, the placental tissue source, clinical indication, and administration route were highly variable across these studies. Fourteen animal studies described the use of placental tissue for tendon injuries, 13 studies for osteoarthritis or articular cartilage injuries, 3 for ligament injuries, and 1 for synovitis. Both placenta-derived culture-expanded cells (epithelial cells or MSCs) and placental tissue allografts were used in animal studies. In all human studies, commercial placental allografts were used. Five of 6 human studies examined the treatment of foot and ankle pathological conditions, and 1 studied the treatment of knee osteoarthritis.


A review of the small number of reported studies revealed a high degree of variability in placental cell types, placental tissue preparation, routes of administration, and treatment regimens, which prohibits making any definitive conclusions. Currently, the clinical use of placenta is limited to only commercial placental tissue allografts, as there are no placenta-derived biological drugs approved for the treatment of orthopaedic sports medicine conditions in the United States. However, this review shows that the application of placental cells or tissue allografts appears to be safe and has potential to improve outcomes for orthopaedic sports medicine indications.

Format: Abstract
Publish: March 2016 10.1007/s10561-015-9530-9.
Author information
  1. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
  2. Comprehensive Tissue Centre, Alberta Health Services, Edmonton, AB, Canada.
  3. Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, T6G 1H9, Canada.
  4. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
  5. Department of Chemical and Materials Engineering, University of Alberta, Edmonton, AB, T6G 1H9, Canada.
Source: Research Article


Amniotic membrane (AM) transplantation is increasingly used in ophthalmological and dermatological surgeries to promote re-epithelialization and wound healing. Biologically active cells in the epithelial and stromal layers deliver growth factors and cytokines with anti-inflammatory, anti-bacterial, anti-immunogenic and anti-fibrotic properties. In this work, confocal microscopy was used to show that our cryopreservation protocol for AM yielded viable cells in both the stromal and epithelial layers with favorable post-transplant outcome. AM was obtained from Caesarean-section placenta, processed into allograft pieces of different sizes (3 cm × 3 cm, 5 cm × 5 cm, and 10 cm × 10 cm) and cryopreserved in 10 % dimethyl sulfoxide using non-linear controlled rate freezing. Post-thaw cell viability in the entire piece of AM and in the stromal and epithelial cell layers was assessed using a dual fluorescent nuclear dye and compared to hypothermically stored AM, while surveys from surgical end-users provided information on post-transplant patient outcomes. There was no significant statistical difference in the cell viability in the entire piece, epithelial and stromal layers regardless of the size of allograft piece (p = 0.092, 0.188 and 0.581, respectively), and in the entire piece and stromal layer of hypothermically stored versus cryopreserved AM (p = 0.054 and 0.646, respectively). Surgical end-user feedback (n = 49) indicated that 16.3 % of AM allografts were excellent and 61.2 % were satisfactory. These results support the expanded clinical use of different sizes of cryopreserved AM allografts and address the issue of orientation of the AM during transplant for the treatment of dermatological defects and ocular surface disorders.

Format: Abstract
Publish: September 2016 10.1177/0363546515612750.
Author information
  1. Division of Sports Medicine and Shoulder Surgery, Rush University School of Medicine, Chicago, Illinois, USA
  2. Division of Sports Medicine and Shoulder Surgery, Rush University School of Medicine, Chicago, Illinois, USA
Source: Research Article


Amniotic membrane (AM)-derived products have been successfully used in ophthalmology, plastic surgery, and wound care, but little is known about their potential applications in orthopaedic sports medicine.


To provide an updated review of the basic science and preclinical and clinical data supporting the use of AM-derived products and to review their current applications in sports medicine.


Systematic review.


A systematic search of the literature was conducted using the Medline, EMBASE, and Cochrane databases. The search term amniotic membrane was used alone and in conjunction with stem cell, orthopaedic, tissue engineering, scaffold, and sports medicine.


The search identified 6870 articles, 80 of which, after screening of the titles and abstracts, were considered relevant to this study. Fifty-five articles described the anatomy, basic science, and nonorthopaedic applications of AM-derived products. Twenty-five articles described preclinical and clinical trials of AM-derived products for orthopaedic sports medicine. Because the level of evidence obtained from this search was not adequate for systematic review or meta-analysis, a current concepts review on the anatomy, physiology, and clinical uses of AM-derived products is presented.


Amniotic membranes have many promising applications in sports medicine. They are a source of pluripotent cells, highly organized collagen, antifibrotic and anti-inflammatory cytokines, immunomodulators, and matrix proteins. These properties may make it beneficial when applied as tissue engineering scaffolds, improving tissue organization in healing, and treatment of the arthritic joint. The current body of evidence in sports medicine is heavily biased toward in vitro and animal studies, with little to no human clinical data. Nonetheless, 14 companies or distributors offer commercial AM products. The preparation and formulation of these products alter their biological and mechanical properties, and a thorough understanding of these differences will help guide the use of AM-derived products in sports medicine research.

Find a SurForce® Health Care Provider

Looking for a SurForce® health care providers?
We can help, complete our form and we can match you
with the closest provider near your ZIP code.

Call Toll Free 877.880.1862

Subscribe to our mailing list

* indicates required
() - (###) ###-####